The evaluation of serum biomarkers in following up preeclampsia

Preeclampsia is a disease characterized by hypertension, proteinuria and edema that occurs after the 20th gestational week. It is among the most important reasons of maternal/perinatal morbidity and mortality. Although a large number of studies have been carried out, the pathophysiology of the disease is not fully known. Many methods have been proposed for evaluating risk factors leading to preeclampsia. In the past, the methods used to predict preeclampsia have usually been focused on non-biochemical markers, but nowadays there is a shift towards biochemical markers. Recently, many biochemical agents have been started to be used in the prediction of preeclampsia. In this study the evaluation of some serum biomarkers in the following up preeclampsia was aimed. Serum nesfatin, ezrin, placental protein 13, hypoxia inducible factor 1-α subunit (HIF1A), and neurofilin 1 levels were examined with ELISA method. In the study, 90 samples taken from subjects, including pre-treatment preeclampsia (n =35), post-treatment preeclampsia (n = 35) and healthy control (n = 20) groups were evaluated. The data obtained from the study was analyzed with SPSS 22.0. As a result of the statistical analysis, pre-treatment nesfatin-1 and ezrin levels were found significantly lower than post-treatment and the healthy control group and HIF-1A level was found significantly higher. As a result of these analyzes, pre-treatment and post-treatment PP13 levels were found to be significantly higher than the healthy control group. Considering the results obtained from the study, we can say that nesfatin, ezrin, HIF1A, PP13 and NRP1 are important biomarkers for predicting preeclampsia.